Posts With Tag Radiopharm Theranostics

Explore Radiopharm Theranostics Limited's Feb 2025 Form 6-K, detailing director interests & securities changes. Key updates for investors.

Discover Radiopharm Theranostics Limited's key updates for February 2025, including their presentation at the TD Cowen Annual Healthcare Conference. Essential compliance insights included.

Explore Radiopharm Theranostics Limited's February 2025 Form 6-K, detailing their SEC filing, conference participation, and compliance updates.

Discover Radiopharm Theranostics Limited's latest Form 6-K detailing groundbreaking clinical trial data on RAD 101's ability to detect brain metastases, filed on February 10, 2025.

Radiopharm Theranostics Limited's Form 6-K highlights Lantheus's A$8M investment, signaling growth potential. Key compliance details and strategic insights for investors.

Explore Radiopharm Theranostics Limited's Form 6-K report detailing their strategic partnership with Lantheus, a key move for market growth in Australia.

Explore Radiopharm Theranostics Limited's December 2024 report detailing RAD 202's Phase 1 trial approval, reflecting key developments in their therapeutic pipeline and compliance status.

Explore Radiopharm Theranostics Limited's SEC Form 6-K dated Dec 19, 2024, detailing their securities application and compliance efforts for transparency in the U.S. market.

Explore Radiopharm Theranostics Limited's December 2024 Form 6-K report detailing significant announcements, including securities updates and director interests. Stay informed!